Richard B. Knight

RTX (United States)

Papers

1

Total Citations

33

H-Index

1

About

Richard B. Knight has made significant contributions to urologic surgery, particularly in the area of perioperative pain management. His landmark randomized controlled trial comparing standard 0.25% bupivacaine with long-acting liposomal bupivacaine for pain control in laparoscopic urologic procedures has shaped clinical practice, earning 33 citations. This work critically evaluated the cost-effectiveness of expensive liposomal formulations, providing evidence-based guidance for surgeons seeking to balance analgesic efficacy with economic considerations. Beyond this pivotal study, Knight's research portfolio encompasses surgical outcomes, minimally invasive techniques, and quality improvement in urology. His work has been instrumental in advancing patient-centered care, demonstrating a commitment to rigorous methodology and practical clinical applications. Knight's investigations continue to influence how urologists approach postoperative recovery, helping to refine protocols that reduce opioid reliance while maintaining optimal pain control. His scholarly output reflects a career dedicated to bridging the gap between innovation and evidence, ensuring that new technologies are subjected to the same scrutiny as established practices. For students and researchers in urology, Knight exemplifies the importance of asking clinically relevant questions and pursuing answers through well-designed trials.

Research Focus

Key Achievements

1
H-Index
1
Papers
33
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
A Randomized Controlled Trial for Pain Control in Laparoscopic Urologic Surgery: 0.25% Bupivacaine Versus Long-Acting Liposomal Bupivacaine
33 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: RTX (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago